Boehringer Ingelheim and NascaCell announce research collaboration on aptamers

18-Feb-2005

Boehringer Ingelheim and NascaCell announced that they have entered into a research collaboration on aptamer based target validation and drug discovery. Under the agreement, NascaCell will provide Boehringer with custom aptamers for therapeutic targets.

"We are delighted to work together with Boehringer's high-class research team", said Dr. Andreas Jenne, NascaCell's managing director. "Within our collaboration aptamers will be used to identify new druggable sites on protein targets. Our approach takes advantage of the unique properties of aptamers to specifically inactivate a particular functional epitope of a protein. Such aptamers may be subsequently used to discover novel small molecule lead compounds."

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...